Biotts, the biopharmaceutical company developing the unique and patented MTC-Y transdermal drug delivery technology, has been granted another patent in the US. The patent covers the MTC-A4 formulation, which has anaesthetic properties and is effective within minutes of application (compared to around 30 minutes for competing products). Expanding the patent cloud is extremely important from […]
Read the full articleEycore has signed a letter of intent with Creotech Instruments, the company announced at a press conference. The companies will collaborate on the design and construction of satellite platforms equipped with SAR radar instruments. Synthetic Aperture Radar (SAR) is a technology that allows continuous observation of the Earth’s surface regardless of weather conditions or time […]
Read the full article
,,Investors love to earn money with him, scientists spread their wings with him, and their inventions bring millions of dollars. Konrad Pankiewicz, with his open mind and ego in control, is fishing for pearls in an academic crucible.’’ This is what the headline of the July 2017 article published on the Puls Biznesu portal says. […]
Read the full articleXTPL published its financial results for 2023 during a video conference on 26 April. The company generated total revenues of PLN 15.5 million in 2023, including PLN 13.4 million in revenues from the sale of products and services. This is the highest result in the history of the company’s development and an increase of 21% […]
Read the full articleOncoSNAAT is a key project for Genomtec from the perspective of increasing the company’s value and a potential M&A transaction. For this project, the Company has secured funding in excess of PLN 10 million, which was successfully raised from the Company’s shareholders and a foreign investor. These funds guarantee the acceleration of the work. The […]
Read the full articleWrocław-based biopharmaceutical company Biotts has filed a patent application for transdermal semaglutide and other GLP-1 molecules in the US and plans to launch the finished product by the end of 2026. According to Reuters, the market for semaglutide and similar drugs using GLP-1 analogues will reach $100 billion in annual sales this decade. The company […]
Read the full articleTerrabio, developer of the Terralyzer® mobile rtPCR genetic analyser, has officially completed its EMC assessment.This means that the unique and compact rtPCR platform Terralyzer® does not interfere with the operation of other devices and is immune to emissions from other devices. This is another milestone in the commercialisation of this solution. Follow the company’s progress […]
Read the full article